Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging

Simple item page
dc.contributor.authorŠuráňová, Markétacs
dc.contributor.authorĎuriš, Miroslavcs
dc.contributor.authorŠtenglová Netíková, Irenacs
dc.contributor.authorBrábek, Jancs
dc.contributor.authorHorák, Tomášcs
dc.contributor.authorJůzová, Veronikacs
dc.contributor.authorChmelík, Radimcs
dc.contributor.authorVeselý, Pavelcs
dc.coverage.issue6cs
dc.coverage.volume14cs
dc.date.accessioned2023-07-25T10:53:32Z
dc.date.available2023-07-25T10:53:32Z
dc.date.issued2023-06-01cs
dc.description.abstractSolid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented.en
dc.formattextcs
dc.format.extent2689-2708cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationBiomedical Optics Express. 2023, vol. 14, issue 6, p. 2689-2708.en
dc.identifier.doi10.1364/BOE.488630cs
dc.identifier.issn2156-7085cs
dc.identifier.orcid0000-0001-8256-1175cs
dc.identifier.orcid0000-0003-2383-1512cs
dc.identifier.orcid0000-0001-5410-4794cs
dc.identifier.orcid0000-0003-3420-395Xcs
dc.identifier.other183847cs
dc.identifier.researcheridGQP-0470-2022cs
dc.identifier.researcheridD-7616-2012cs
dc.identifier.researcheridD-9921-2012cs
dc.identifier.scopus57346567800cs
dc.identifier.scopus6603192372cs
dc.identifier.urihttp://hdl.handle.net/11012/213614
dc.language.isoencs
dc.publisherOpticacs
dc.relation.ispartofBiomedical Optics Expresscs
dc.relation.urihttps://opg.optica.org/boe/fulltext.cfm?uri=boe-14-6-2689&id=530666cs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/2156-7085/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectIn-vitroen
dc.subjectMulti-fielden
dc.subjectQuantitative phase imagingen
dc.subjectRapid testen
dc.subjectRepurposingen
dc.subjectSimultaneous analysisen
dc.subjectSolid tumorsen
dc.subjectTime-lapse recordingen
dc.subjectTumor cell linesen
dc.subjectTumor metastasisen
dc.titlePrimary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imagingen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-183847en
sync.item.dbtypeVAVen
sync.item.insts2023.10.24 12:58:01en
sync.item.modts2023.10.24 12:15:01en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Experimentální biofotonikacs
thesis.grantorVysoké učení technické v Brně. Fakulta strojního inženýrství. Ústav fyzikálního inženýrstvícs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
boe1462689.pdf
Size:
4 MB
Format:
Adobe Portable Document Format
Description:
boe1462689.pdf
Download
Collections
Experimentální biofotonika
Ústav fyzikálního inženýrství